This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Biotech Stock Mailbag: PTC Therapeutics, Vanda, MannKind

Stocks in this article: PTCTSRPTVRTXVNDAMNKD

Kishore S. writes:

"Good article and you seem to have uncovered some points/facts that the whole world missed out on including Baker Brothers. Is it possible that everyone was so blind to the obvious that small investors like me have to get burnt so badly? Anyway, good job on adding up the numbers where all the other experts are blind."

The lesson here is know what you own. Do your own homework. Don't just buy a stock because a big hedge fund owns it.

Avery_t writes:

Even if tasilmelteon doesn't work for its initial target population or end goal, it might still be a great sleep agent for the general population of insomniacs, who have very, very few choices. Any compound that induces sleep without A) being addictive or B) lowering the quality of sleep is a potential gold mine. It could be a paint thinner that's discovered to work as a sleep agent. It doesn't matter.

Takeda tried with this approach with Rozerem but failed badly. Rozerem (scientific name: ramelteon) is very similar structurally to tasimelteon. Both drugs are melatonin agonists that hit the MT1 and MT2 receptors in the brain. (Unlike other sleep drugs, like Ambien, which works against GABA receptors.)

Rozerem was approved as an insomnia drug in 2005, which led to this memorable commercial featuring Abe Lincoln and a talking beaver.

Great ad. Unfortunately, Rozerem is a mediocre prescription sleep aid.

You have to go back a bunch of years, but Vanda's original idea was to develop tasimelteon as a sleeping pill. Phase III studies were run which produced okay results -- nothing spectacular. But then Rozerem was approved and flopped commercially, forcing Vanda to go disease-shopping for another way to develop tasimelteon. That's how the idea of using the drug to treat non-24 was hatched.

Tasimelteon has no alternative future as a regular sleeping pill.

Lazard Capital analyst Josh Schimmer is the sell-side's most vocal Vanda table pounder. On Wednesday, citing his "access to management," Schimmer came to tasimelteon's defense:

The FDA worked with VNDA during SET/RESET to optimize endpoint selection. As such, we have little concern that the endpoints shifted over time, and the company was not changing endpoints surreptitiously in response to blinded or unblinded data. Phase 2 results revealed too much noise exists in N24 to use TST as an endpoint, so the FDA recommended more suitable assessments. The ultimate choice of endpoints was finalized in conjunction with the FDA before the data set was locked. The primary endpoint of entrainment was selected as a true measure of the disease's root cause and is strongly supported by KOLs. As a biomarker, however, it was important that secondary endpoints which capture the effects of tasimelteon were positive, which they were. The N24 Clinical Response Scale was created by the company, but validated in the SET/RESET studies by key secondary endpoints. Furthermore, the FDA agreed in the pre-NDA meeting that the data were adequate to support approval.

Schimmer engages in some wishful thinking. The FDA told Vanda during a pre-NDA meeting that the tasimelteon data "were adequate to support approval." Really? That's a remarkable statement for Vanda to make because it re-writes decades of regulatory regulations and precedent.

Why spend 10 months reviewing a drug for safety and efficacy when it can be done over the course of a 60-minute pre-NDA meeting?

I'd like to hear more from Schimmer or Vanda explaining precisely how the clinical response scale -- made up by Vanda during the last months of the tasimelteon trial -- was "validated" by other endpoints in the same trial.

3 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,802.81 -7.25 -0.04%
S&P 500 2,066.72 +3.22 0.16%
NASDAQ 4,746.6990 +33.7290 0.72%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs